SCHEMBL3216541

SCHEMBL3216541

CCCCCCCCCCCC(=O)OC(Cl)C(Cl)Cl

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.63
MAPT P10636 3/20 0.59
MAPK1 P28482 3/20 0.59
ALDH1A1 P00352 2/20 0.56
DGKA P23743 1/20 0.52
PRKCA P17252 1/20 0.51
PRKCE Q02156 1/20 0.51
PRKCQ Q04759 1/20 0.51
PRKCD Q05655 1/20 0.51
CYP1A2 P05177 2/20 0.47
TSHR P16473 2/20 0.47
MEN1 O00255 1/20 0.47
GMNN O75496 1/20 0.47
HSP90AA1 P07900 1/20 0.47
BLM P54132 1/20 0.47
KMT2A Q03164 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
NR1H4 Q96RI1 1/20 0.47
TP53 P04637 1/20 0.47
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8945740 1.00 LMNA (0.63) LMNAMAPTMAPK1ALDH1A1DGKA
SCHEMBL8945623 1.00 LMNA (0.63) LMNAMAPTMAPK1ALDH1A1DGKA
SCHEMBL8154447 0.98 LMNA (0.60) LMNAMAPTMAPK1ALDH1A1DGKA
SCHEMBL9095817 0.92 LMNA (0.52) LMNAMAPTMAPK1ALDH1A1DGKA
SCHEMBL31112799 0.87 LMNA (0.67) LMNAMAPTMAPK1ALDH1A1DGKA
SCHEMBL31112945 0.87 LMNA (0.67) LMNAMAPTMAPK1ALDH1A1DGKA
SCHEMBL31112808 0.87 LMNA (0.67) LMNAMAPTMAPK1ALDH1A1DGKA
SCHEMBL8346746 0.84 LMNA (0.68) LMNAMAPTMAPK1ALDH1A1DGKA
SCHEMBL8769110 0.84 LMNA (0.68) LMNAMAPTMAPK1ALDH1A1DGKA
SCHEMBL28289715 0.84 LMNA (0.68) LMNAMAPTMAPK1ALDH1A1DGKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2077987-B1 MANDELIC ACID DERIVATIVES AND PREPARATION THEREOF TRANSTECH PHARMA INC (US) 2010-11-24 EP disclosed
US-20100036150-A1 MANDELIC ACID DERIVATIVES AND PREPARATION THEREOF TRANSTECH PHARMA, INC. 2010-02-11 US disclosed
EP-2077987-A1 MANDELIC ACID DERIVATIVES AND PREPARATION THEREOF Transtech Pharma, Inc. (US) 2009-07-15 EP disclosed
WO-2008051563-A1 MANDELIC ACID DERIVATIVES AND PREPARATION THEREOF TRANSTECH PHARMA, INC. (US) 2008-05-02 WO disclosed
US-6045720-A EXHIBITS A FERROELECTRIC LIQUID CRYSTALLINE PHASE AND AN ANTIFERROELECTRIC LIQUID CRYSTALLINE PHASE BY ITSELF; HIGH SPEED RESPONSE; DISPLAY ELEMENT; OPTICAL SWITCHING ELEMENT; CHISSO CORPORATION (JP) 2000-04-04 US disclosed
EP-0774452-B1 Optically active compounds having plural chiral centers and the production thereof CHISSO CORP (JP) 2000-01-26 EP disclosed
EP-0428392-B1 Processes for the preparation of optically active compounds having plural chiral centers CHISSO CORP (JP) 1998-05-27 EP disclosed
EP-0454463-B1 Process for producing epoxyalcohols of high optical purity ARCO CHEM TECH (US) 1997-08-13 EP disclosed
EP-0774452-A1 Optically active compounds having plural chiral centers and the production thereof Chisso Corporation (JP) 1997-05-21 EP disclosed
US-5574182-A HYDROLYSING 3-HYDROXYCARBOXYLIC ACID, CYCLIZING ESTER TO FORM 1,3-DIOXAN-4-ONE, DECYCLIZATION AND ESTERIFICATION CHISSO CORPORATION (JP) 1996-11-12 US disclosed
EP-0454463-A2 Process for producing epoxyalcohols of high optical purity ARCO Chemical Technology, L.P. (US) 1991-10-30 EP disclosed
EP-0428392-A2 Optically active compounds having plural chiral centers and the production thereof Chisso Corporation (JP) 1991-05-22 EP disclosed
US-4971909-A TRANSESTERIFICATION IN THE PRESENCE OF HYDROLASES CHISSO CORPORATION (JP) 1990-11-20 US disclosed
US-4962031-A SPECIFIC COMPOUNDS HAVING HYDROXYL GROUPS REACTED WITH ESTERS IN PRESENCE OF HYDROLASES CHISSO CORPORATION (JP) 1990-10-09 US disclosed
US-4916074-A ENZYMATIC TRANS ESTERIFICATION OF ALCOHOL WITH TRIGLYCERIDES; PSEUDOMONAS-DERIVED ENZYME CHISSO CORPORATION (JP) 1990-04-10 US disclosed
US-4882451-A SILYL ALCOHOLS OR ESTERS CHISSO CORPORATION (JP) 1989-11-21 US disclosed
EP-0304706-A2 Process for producing optically active compounds having pyridine skeletons CHISSO CORPORATION (JP) 1989-03-01 EP disclosed
EP-0290878-A2 Optically active compounds and process for producing thereof Chisso Corporation (JP) 1988-11-17 EP disclosed
EP-0288994-A2 Process for producing optically active compounds Chisso Corporation (JP) 1988-11-02 EP disclosed
EP-0266217-A2 Process for producing optically active compounds CHISSO CORPORATION (JP) 1988-05-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100036150-A1 MANDELIC ACID DERIVATIVES AND PREPARATION THEREOF CYP8B1, CYP51A1, COMT LMNA 1188/4885MAPT 2796/4885MAPK1 1103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.